U.S. markets close in 16 minutes
  • S&P 500

    4,419.24
    +7.45 (+0.17%)
     
  • Dow 30

    35,121.58
    +60.03 (+0.17%)
     
  • Nasdaq

    14,835.41
    -1.58 (-0.01%)
     
  • Russell 2000

    2,215.41
    +5.76 (+0.26%)
     
  • Crude Oil

    72.10
    +0.03 (+0.04%)
     
  • Gold

    1,797.00
    -4.80 (-0.27%)
     
  • Silver

    25.25
    +0.01 (+0.05%)
     
  • EUR/USD

    1.1804
    +0.0033 (+0.28%)
     
  • 10-Yr Bond

    1.2760
    -0.0100 (-0.78%)
     
  • GBP/USD

    1.3816
    +0.0062 (+0.45%)
     
  • USD/JPY

    110.4060
    -0.1040 (-0.09%)
     
  • BTC-USD

    39,771.38
    +5,302.32 (+15.38%)
     
  • CMC Crypto 200

    946.76
    +31.27 (+3.42%)
     
  • FTSE 100

    7,025.43
    -2.15 (-0.03%)
     
  • Nikkei 225

    27,833.29
    +285.29 (+1.04%)
     

J&J buys bowel drug license option from Isis Pharma for $835 mln

Jan 5 (Reuters) - Johnson & Johnson will pay Isis Pharmaceuticals Inc up to $835 million for the option to license three drugs targeting autoimmune diseases in the bowel.

Isis Pharmaceuticals said it will receive $35 million in an upfront payment and will be eligible to receive royalties on sales of the drugs.

Janssen Biotech Inc, a unit of J&J, will have the right to license a drug from each of the programs once a candidate is identified, the Carlsbad, California-based developer said.

(Reporting by Vidya L Nathan in Bengaluru; Editing by Savio D'Souza)